BRPI1014595A2 - procedimento de obtenção de novos derivados naftaleno para o diagnóstico in vivo de doença de alzheimer - Google Patents

procedimento de obtenção de novos derivados naftaleno para o diagnóstico in vivo de doença de alzheimer

Info

Publication number
BRPI1014595A2
BRPI1014595A2 BRPI1014595A BRPI1014595A BRPI1014595A2 BR PI1014595 A2 BRPI1014595 A2 BR PI1014595A2 BR PI1014595 A BRPI1014595 A BR PI1014595A BR PI1014595 A BRPI1014595 A BR PI1014595A BR PI1014595 A2 BRPI1014595 A2 BR PI1014595A2
Authority
BR
Brazil
Prior art keywords
alzheimer
disease
procedure
naphthalene derivatives
obtaining new
Prior art date
Application number
BRPI1014595A
Other languages
English (en)
Inventor
Alejandro Perera Pintado
Anaís Prats Capote
Carlos Serafin Pérez Martínez
Chryslaine Rodriguez-Tanty
Hermán Vélez Castro
Marquiza Sablón Carrazana
Pedro Valdés Sosa
Rafaela Perez Perera
Rosa María López Barroso
Suchitil Rivera Marrero
Original Assignee
Ct De Neurociencias De Cuba Cubana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Neurociencias De Cuba Cubana filed Critical Ct De Neurociencias De Cuba Cubana
Priority to BR122020016643A priority Critical patent/BR122020016643B8/pt
Publication of BRPI1014595A2 publication Critical patent/BRPI1014595A2/pt
Publication of BRPI1014595B1 publication Critical patent/BRPI1014595B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/07—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI1014595-8A 2009-04-17 2010-04-17 Compostos derivados de naftaleno e procedimento para preparação dos mesmos BRPI1014595B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020016643A BR122020016643B8 (pt) 2009-04-17 2010-04-17 compostos derivados de naftaleno, procedimento para a preparação de derivados de alquilfluoronaftaleno e procedimento para marcação dos compostos com 99mtc

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2009-0057 2009-04-17
CU2009000057A CU23844B1 (es) 2009-04-17 2009-04-17 Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
PCT/CU2010/000001 WO2010118706A2 (es) 2009-04-17 2010-04-17 Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer

Publications (2)

Publication Number Publication Date
BRPI1014595A2 true BRPI1014595A2 (pt) 2016-04-05
BRPI1014595B1 BRPI1014595B1 (pt) 2021-07-06

Family

ID=45000046

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI1014595-8A BRPI1014595B1 (pt) 2009-04-17 2010-04-17 Compostos derivados de naftaleno e procedimento para preparação dos mesmos
BR122020016643A BR122020016643B8 (pt) 2009-04-17 2010-04-17 compostos derivados de naftaleno, procedimento para a preparação de derivados de alquilfluoronaftaleno e procedimento para marcação dos compostos com 99mtc

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020016643A BR122020016643B8 (pt) 2009-04-17 2010-04-17 compostos derivados de naftaleno, procedimento para a preparação de derivados de alquilfluoronaftaleno e procedimento para marcação dos compostos com 99mtc

Country Status (16)

Country Link
US (2) US9764047B2 (pt)
EP (2) EP2436666B1 (pt)
BR (2) BRPI1014595B1 (pt)
CA (1) CA2789869C (pt)
CU (1) CU23844B1 (pt)
DK (1) DK2436666T3 (pt)
ES (2) ES2478442T3 (pt)
HR (1) HRP20140628T1 (pt)
HU (1) HUE042030T2 (pt)
MX (2) MX2011013405A (pt)
MY (1) MY162719A (pt)
PL (1) PL2436666T3 (pt)
PT (1) PT2436666E (pt)
SI (1) SI2436666T1 (pt)
SM (1) SMT201400118B (pt)
WO (1) WO2010118706A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20130027A7 (es) * 2013-02-28 2014-10-30 Ct De Neurociencias De Cuba Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales
US9850183B2 (en) 2014-06-27 2017-12-26 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
EP3242688B1 (en) 2015-01-09 2020-01-29 Reiley Pharmaceuticals, Inc. Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
CU24583B1 (es) * 2018-11-06 2022-02-04 Centro De Neurociencias De Cuba Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri)
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US12251991B2 (en) 2020-08-20 2025-03-18 Denso International America, Inc. Humidity control for olfaction sensors
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US12269315B2 (en) 2020-08-20 2025-04-08 Denso International America, Inc. Systems and methods for measuring and managing odor brought into rental vehicles
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US12377711B2 (en) 2020-08-20 2025-08-05 Denso International America, Inc. Vehicle feature control systems and methods based on smoking
CU24720B1 (es) 2020-11-24 2024-10-09 Centro De Neurociencias De Cuba Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2976305A (en) * 1958-07-30 1961-03-21 Albert Ag Chem Werke Salts of dithiocarbamic acids derived from amino amides of dicarboxylic acids
US4327022A (en) * 1973-08-16 1982-04-27 Sterling Drug Inc. Heterocyclic alkyl naphthols
US4615876A (en) 1983-04-25 1986-10-07 Curators Of The University Of Missouri Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides
DE3687467T2 (de) 1985-03-11 1993-04-29 Amersham Int Plc Komplexe von technetium-99m mit propylen-amin-oximen.
GB8601003D0 (en) 1986-01-16 1986-02-19 Amersham Int Plc Labelling blood cells
GB8603778D0 (en) * 1986-02-15 1986-03-19 Beecham Group Plc Chemical process
DE3631013A1 (de) * 1986-09-12 1988-03-24 Thomae Gmbh Dr K Neue naphthylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US4933156A (en) 1987-04-08 1990-06-12 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
US5008099A (en) 1987-04-08 1991-04-16 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
CN1072020A (zh) 1991-10-28 1993-05-12 国营八二一厂 多用途血液稀释剂
US5690904A (en) 1993-07-12 1997-11-25 Amersham International Plc Diagnostic radiopharmaceutical compounds (That)
US6417178B1 (en) 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US5955472A (en) * 1995-11-02 1999-09-21 Warner-Lambert Company Naphthylazo inhibition of amyloidosis
AU759945B2 (en) 1998-08-20 2003-05-01 Regents Of The University Of California, The Methods for labeling beta-amyloid plaques and neurofibrillary tangles
TW438596B (en) 1999-02-26 2001-06-07 Inst Of Nuclear Energy Res Roc Preparation of a new technetium-99m radiopharmaceutical kit for dopamine transporter imaging
DE10018199A1 (de) * 2000-04-12 2001-10-31 Few Chemicals Gmbh Fluoreszenzmarker
IT1317048B1 (it) 2000-06-23 2003-05-26 Sigma Tau Ind Farmaceuti Uso dell'acido pamoico o di un suo derivato, o di un suo analogo, perla preparazione di un medicamento per il trattamento di patologie
GB0023467D0 (en) * 2000-09-25 2000-11-08 Btg Int Ltd Amine compounds
US6379650B1 (en) 2001-03-19 2002-04-30 Wesley Scott Ashton Technetium 99m-N2S2-congo red complexes utilizing diamide dithiolate ligand systems for radioimaging
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
CA2444214A1 (en) 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
WO2002098846A1 (en) * 2001-06-05 2002-12-12 Eli Lilly And Company Sulfonamide derivatives
CN1299777C (zh) 2001-08-27 2007-02-14 宾夕法尼亚州大学理事会 茋衍生物及其用于结合和成像淀粉样蛋白斑的用途
WO2004027388A2 (en) * 2002-09-23 2004-04-01 Chromagen, Inc. Novel green and orange fluorescent labels and their uses
JP2007504283A (ja) 2003-05-20 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア β−アミロイド斑に作用物質を結合させる方法
WO2005077962A2 (en) * 2004-02-10 2005-08-25 Purdue Research Foundation Crowned dithiocarbamate metal complexes and methods for their use
US7803351B2 (en) 2004-08-20 2010-09-28 Washington University Blood brain barrier permeation peptides
WO2006083378A2 (en) 2004-11-29 2006-08-10 The Regents Of The University Of California IN VIVO MONITORING OF β-AMYLOID PLAQUES AND NEUROFIBRILLARY TANGLES
EP2213652B1 (en) 2004-12-17 2014-10-22 The Trustees of The University of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
JPWO2006115137A1 (ja) * 2005-04-22 2008-12-18 キッセイ薬品工業株式会社 ２−アミノベンズイミダゾール誘導体及びその医薬用途
EA200801120A1 (ru) * 2005-10-18 2008-08-29 Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. Нафтильные производные в качестве ингибиторов агрегирования бета-амилоида
AU2007209853B2 (en) * 2006-01-30 2012-07-12 University Of North Dakota Divalent metal ion sensors and binders
US8337941B2 (en) * 2006-07-27 2012-12-25 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
GB0819280D0 (en) * 2008-10-21 2008-11-26 Gen Electric Imgaing and radiotherapy methods

Also Published As

Publication number Publication date
CA2789869A1 (en) 2010-10-21
DK2436666T3 (da) 2014-07-14
ES2692072T3 (es) 2018-11-30
US20150217005A1 (en) 2015-08-06
HRP20140628T1 (hr) 2014-11-21
SMT201400118B (it) 2014-11-10
CU23844B1 (es) 2012-10-15
SI2436666T1 (sl) 2014-09-30
WO2010118706A3 (es) 2010-12-02
EP2860169B1 (en) 2018-08-29
MX2011013405A (es) 2012-10-23
US9764047B2 (en) 2017-09-19
EP2860169A3 (en) 2015-10-21
MY162719A (en) 2017-07-14
PL2436666T3 (pl) 2014-09-30
WO2010118706A4 (es) 2011-01-20
EP2860169A2 (en) 2015-04-15
HUE042030T2 (hu) 2019-06-28
US20120321560A1 (en) 2012-12-20
WO2010118706A2 (es) 2010-10-21
BR122020016643B8 (pt) 2021-07-27
EP2436666B1 (en) 2014-04-09
US10155053B2 (en) 2018-12-18
CU20090057A6 (es) 2011-10-14
ES2478442T3 (es) 2014-07-22
MX338943B (es) 2016-05-06
EP2436666A4 (en) 2013-02-13
CA2789869C (en) 2016-06-21
BR122020016643B1 (pt) 2021-03-30
BRPI1014595B1 (pt) 2021-07-06
PT2436666E (pt) 2014-07-18
EP2436666A2 (en) 2012-04-04

Similar Documents

Publication Publication Date Title
BRPI1014595A2 (pt) procedimento de obtenção de novos derivados naftaleno para o diagnóstico in vivo de doença de alzheimer
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
PT2504005E (pt) Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas
WO2011045415A3 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
BR112012011507A2 (pt) "remoção não invasiva de gordura"
BRPI1012993A2 (pt) "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro"
PT2426148E (pt) Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
HRP20190031T1 (hr) Sintetski triterpenoidi i postupci njihove upotrebe u liječenju bolesti
BRPI1010280A2 (pt) instrumentos cirúrgicos para montagem in vivo
PL2442814T3 (pl) Bifidobacteria do leczenia cukrzycy i pokrewnych chorób
PT2530093T (pt) Composto de indocianina, método de síntese do mesmo, método de purificação do mesmo, composição de diagnóstico utilizando o composto de indocianina, e dispositivo para medição da cinética in vivo e dispositivo para visualização da circulação utilizando a composição de diagnóstico
EP2387712A4 (en) NON-INVASIVE MEASUREMENT OF FLAVONOID COMPOUNDS IN BIOLOGICAL TISSUE
EP2795325A4 (en) PROCESS FOR THE DIAGNOSIS OF MORBUS ALZHEIMER
IL230441A0 (en) Diagnosis of Alzheimer's disease
BRPI0917478A2 (pt) uso de beta-lactamase bacteriana para diagnóstico in vitroe geração de imagem, diagnóstico e terapêutica in vivo
EP2198292A4 (en) IMPROVED MORBUS ALZHEIMER DIAGNOSIS
HRP20170238T1 (hr) Postupak za pripremu vodenih otopina hiperpolariziranih molekula
EP2463381A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF CERVICAL INTRAITITHELIAL NEOPLASIA AND NUTRITIONAL CANCER
EP2320939A4 (en) TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
EP2198040A4 (en) IN VIVO FIGURE OF MYELIN
ZA201100165B (en) Use of hdac inhibitors for the treatment of hodgkin's disease
BRPI0907956A2 (pt) Uso de ranolazina para o tratamento de doenças cardiovasculares
EP2421554A4 (en) TISSUE KALLICREIN FOR THE TREATMENT OF HUNTINGTON'S DISEASE
BR112012002077A2 (pt) processos e métodos para diagnóstico de doença de alzheimer
EP2791676A4 (en) PROCESS FOR THE DIAGNOSIS OF MORBUS ALZHEIMER

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/04/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.